Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Cejuela et al., 2022)
However, it is encouraging that preclinical and early human studies suggest that GLP-1 agonism appears broadly protective: indeed clinical trials of these agents are being initiated in cardiovascular disease (SELECT and SOUL trials, see below), NASH, and neurodegeneration (Alzheimers and Parkinsons)
Journal of Clinical Endocrinology & Metabolism, 60(1), 114-119
Current evidence suggests that GLP-1 receptor agonists do not appear to cause disproportionate muscle loss compared to equivalent weight loss achieved through other methods, though individual responses may vary
However, some users have reported experiencing side effects related to sleep, such as difficulty falling asleep and staying asleep
